BC Innovations | Feb 13, 2018
Distillery Therapeutics


INDICATION: Ovarian cancer Cell culture and mouse studies suggest inhibiting MENA could help treat metastases of serous ovarian cancer. In a panel of serous ovarian cancer cell lines, expression of the MENA isoform MENAΔv6 was...
BC Extra | Jul 6, 2017
Preclinical News

Paper shows Tie2 inhibition decreases chemotherapy-induced metastasis

In a paper published in Science Translational Medicine , scientists showed that chemotherapy to treat breast cancer induces metastasis through a tumor microenvironment of metastasis (TMEM) mechanism, which has been used in the clinic to determine...
BC Week In Review | Dec 9, 2016
Company News

Amryt, Aegerion deal

Aegerion granted Amryt exclusive rights to market Lojuxta lomitapide in the European Economic Area (EEA), Middle East and North Africa (MENA), Israel and Turkey. Aegerion is eligible for milestone payments, plus royalties. Amryt will be...
BC Week In Review | May 23, 2016
Company News

Alexza, Ferrer deal

Grupo Ferrer’s Ferrer Pharma subsidiary will acquire Alexza for $0.90 per share in cash. The deal values Alexza at $19.6 million based on 21.7 million shares outstanding on May 11. Alexza shareholders will also receive...
BC Week In Review | Dec 7, 2015
Company News

Univercells, Takeda deal

Univercells and Takeda partnered to produce affordable vaccines for emerging countries, including South Africa, Turkey, China, South Korea and countries in the Middle East and North Africa (MENA) region. The partners will tailor and integrate...
BC Week In Review | Apr 13, 2015
Clinical News

Remimazolam: Phase III started

Paion began a double-blind, placebo-controlled, U.S. Phase III trial to compare IV remimazolam vs. midazolam in about 460 patients undergoing colonoscopy. Patients will receive 5 mg remimazolam for induction and 2.5 mg top-ups for maintenance....
BC Week In Review | Apr 7, 2014
Clinical News

ICEF15: Phase IIb started

Innovacell and partner Norgine began the double-blind, placebo-controlled, dose-finding, European Phase IIb STEFFI trial to evaluate ICEF15 injected into the external anal sphincter muscle using Innovacell's injection device in about 250 patients with fecal incontinence...
BC Week In Review | Mar 17, 2014
Company News

Hikma Pharmaceuticals management update

Hikma Pharmaceuticals plc (LSE:HIK), London, U.K.   Business: Generics, Drug delivery   Promoted: Mazen Darwazah to president and CEO of Middle East and North Africa (MENA) and emerging markets, a newly created position; and Bassam...
BC Week In Review | Dec 23, 2013
Company News

Algorithm, Iroko, Fahrenheit deal

Iroko granted Algorithm exclusive rights to develop and commercialize Zorvolex submicron diclofenac in the Middle East and North Africa (MENA) region. Separately, Iroko granted Fahrenheit exclusive rights to develop and commercialize the product in Indonesia....
BC Week In Review | Dec 23, 2013
Company News

Innovacell, Norgine deal

The companies will co-develop Innovacell's ICEF15 in Europe, the South African Development Community (SADC) and the Middle East and North Africa (MENA). The companies plan to start a Phase IIb trial to evaluate the ICEF15...
Items per page:
1 - 10 of 16